Case Analysis on Real Life Incidence of Photodynamic Therapy (PDT) Safety Outcomes
NCT01203163 · Status: WITHDRAWN · Type: OBSERVATIONAL
Last updated 2012-05-09
Summary
Three main adverse reactions, namely photosensitivity (reaction that is similar to sunburn), oesophageal stenosis (narrowing or closure of the food pipe), perforation of the treated area (a tear or puncture of the tissue), have been identified in research studies evaluating photodynamic therapy (PDT) with porfimer sodium. Because of the low incidence of the disease or the variation in the occurrence of these adverse reactions among different indications, it is difficult to determine the occurrence and frequency of these safety issues in routine clinical practice.
This post-marketing safety surveillance registry is set-up to evaluate the safety of PDT using porfimer sodium. A registry allows the collection of data to evaluate real-world results in the practice of medicine. The registry will monitor the patient's health and any events, with a main focus on photosensitivity, oesophageal stenosis, and perforation of the treated area. This registry will involve 500 patients, across 20 to 36 hospitals in the US and Europe, scheduled to receive an injection of porfimer sodium with PDT for the treatment of lung cancer, esophageal \[food pipe\] cancer, or high-grade dysplasia (HGD) (precancerous change in the food pipe tissue) in Barrett's esophagus.
Conditions
- Esophageal Cancer
- Lung Cancer
- Barrett's Esophagus
Sponsors & Collaborators
-
Pinnacle Biologics Inc.
lead INDUSTRY
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
More Related Trials
-
Photodynamic Therapy in Treating Patients With Early Esophageal Cancer
NCT00002935 ·Status: COMPLETED ·Phase: PHASE2
-
Study for Determination of Feasibility and Toxicity of Pre-Treatment With HPPH (2-1[1-Hexyloxyethyl]-2 Devinyl Pyropheophorbide-a) Photodynamic Therapy Prior to Chemoradiation in Non-Operable Patients With Obstructive Esophageal Cancer
NCT01035437 ·Status: WITHDRAWN ·Phase: NA
-
Biomarkers in Phototherapy of Barrett's Esophagus
NCT00587600 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Hematoporphyrin Photodynamic Therapy for Esophageal Cancer
NCT06437288 ·Status: ENROLLING_BY_INVITATION ·Phase: PHASE4
-
HPPH Photodynamic Therapy for Patients With Esophageal Cancer
NCT03757754 ·Status: UNKNOWN ·Phase: PHASE1
-
Clinical Study of Time Optimizing of Endoscopic Photodynamic Therapy on Esophageal and/or Gastric Cardiac Cancer
NCT02628665 ·Status: UNKNOWN ·Phase: PHASE3
-
Pulsed Low Dose Rate Radiation With Concurrent Chemotherapy for Non-Small Cell Lung Cancer and Esophageal Cancer
NCT03094884 ·Status: UNKNOWN ·Phase: PHASE1
-
A Trial of a New Type of Photodynamic Therapy (VTP) in the Treatment of Patients With Cancer of the Esophagus Who Have Trouble Swallowing
NCT03133650 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
A Comparative Study of Endoscopic Submucosal Dissection and Photodynamic Therapy for Early Esophageal Cancer
NCT05208775 ·Status: UNKNOWN ·Phase: NA
-
Stereotactic Boost for Oropharyngeal Squamous Cell Carcinoma
NCT01586182 ·Status: WITHDRAWN ·Phase: PHASE1/PHASE2
-
Palliative Radiotherapy and Brachytherapy for Oesophageal Cancer Dysphagia
NCT00665197 ·Status: COMPLETED ·Phase: PHASE3
-
Proton Beam Therapy to Treat Esophageal Cancer
NCT02023541 ·Status: TERMINATED ·Phase: PHASE1
-
The Effect of Caphosol® on the Development of Esophagitis in (N)SCLC Patients Treated With Concurrent Chemo/Radiotherapy
NCT01809756 ·Status: TERMINATED ·Phase: NA
-
The Effect of Ablation Therapy on Barrett's Esophagus
NCT00587314 ·Status: ENROLLING_BY_INVITATION
-
Phase I Dose Escalation of Stereotactic Radiosurgical Boost for Locally Advanced Esophageal Cancer
NCT00368329 ·Status: TERMINATED ·Phase: PHASE1
-
Radiochemotherapy With and Without Dose Escalation in Patients Presenting Locally Advanced or Inoperable Carcinoma of the Oesophagus
NCT01348217 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Advanced Oesophageal Cancer Study to Compare Quality of Life and Palliation of Dysphagia.
NCT00193882 ·Status: COMPLETED ·Phase: PHASE3
-
Oxaliplatin, Gefitinib, and Radiation Therapy in Treating Patients With Locally Advanced or Metastatic Esophageal Cancer
NCT00093652 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
Comparing Proton Therapy to Photon Radiation Therapy for Esophageal Cancer
NCT03801876 ·Status: RECRUITING ·Phase: PHASE3
-
MnSOD (Esophageal Protectant) to Prevent Esophagitis During Radiation/Chemotherapy Treatment for Non-Small Cell Lung Cancer (NSCLC)
NCT00618917 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
Pre-op Chemo-RT w/CDDP/5FU vs Chemo w/ Docetaxel/Irinotecan in PET Non Responder Resectable Esophagus Cancer
NCT01608464 ·Status: TERMINATED ·Phase: PHASE2
-
Tucidinostat Plus PD-1 Inhibitor and Bevacizumab for Advanced Esophagus Cancer, AEG, Gastric Cancer
NCT05163483 ·Status: RECRUITING ·Phase: PHASE2
-
An Open-label, Single-center, Phase 1/ 2 Study of Chemoradiotherapy and AT-101 in Patients With Locally Advanced Esophageal or Gastroesophageal Junction Cancer
NCT00561197 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
Radiotherapy & Olaparib in COmbination for Carcinoma of the Oesophagus
NCT01460888 ·Status: UNKNOWN ·Phase: PHASE1
-
Radiation Therapy and Paclitaxel, Carboplatin, and Fluorouracil Followed by Esophagectomy in Treating Patients With Locally Advanced Cancer of the Esophagus or Gastroesophageal Junction
NCT00022139 ·Status: COMPLETED ·Phase: PHASE2